Feasibility of Automated Insulin Delivery Guided by Continuous Glucose Monitoring in preterm infants by Beardsall, Kathryn et al.
  F279Beardsall K, et al. Arch Dis Child Fetal Neonatal Ed 2020;105:F279–F284. doi:10.1136/archdischild-2019-316871
Original research
Feasibility of automated insulin delivery guided by 
continuous glucose monitoring in preterm infants
Kathryn Beardsall  ,1,2 Lynn Thomson,1 Daniela Elleri,1 David B Dunger,1 
Roman Hovorka1
To cite: Beardsall K, 
Thomson L, Elleri D, et al. 
Arch Dis Child Fetal Neonatal 
Ed 2020;105:F279–F284.
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
archdischild- 2019- 316871).
1Department of Paediatrics, 
University of Cambridge, 
Cambridge Biomedical Campus, 
Cambridge, Cambridgeshire, UK
2Neonatal Unit, Cambridge 




Department of Paediatrics, 
University of Cambridge, 
Cambridge Biomedical Campus, 
Cambridge CB2 2QQ, UK;  
 kb274@ cam. ac. uk
Received 17 January 2019
Revised 8 July 2019
Accepted 8 July 2019
Published Online First 
9 August 2019
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
What is already known on this topic?
 ► Extremely preterm infants are prone to glucose 
dysregulation, which has been associated with 
adverse outcomes.
 ► Continuous glucose monitoring may help to 
identify hypoglycaemia and hyperglycaemia but 
targeting glucose levels remains challenging.
 ► Closed- loop systems have been used to 
optimise insulin delivery in children with 
diabetes, but they have not been tested in 
neonatal intensive care.
What this study adds?
 ► Closed- loop systems using subcutaneous 
glucose measurements to guide insulin delivery 
may improve glucose control in extremely 
preterm infants.
 ► Closed- loop systems could reduce the risk 
of hypoglycaemia associated with the use of 
insulin in this vulnerable population, but further 
studies are required.
 ► The use of insulin within closed- loop systems 
may help to optimise nutritional intake in 
these babies without increasing the risk of 
hypoglycaemia.
AbsTrACT
Objective Closed- loop systems have been used to 
optimise insulin delivery in children with diabetes, but 
they have not been tested in neonatal intensive care. 
Extremely preterm infants are prone to hyperglycaemia 
and hypoglycaemia; both of which have been associated 
with adverse outcomes. Insulin sensitivity is notoriously 
variable in these babies and glucose control is time- 
consuming, with management requiring frequent 
changes of dextrose- containing fluids and careful 
monitoring of insulin treatment. We aimed to evaluate 
the feasibility of closed- loop management of glucose 
control in these infants.
Design and setting Single- centre feasibility study with 
a randomised parallel design in a neonatal intensive care 
unit. Eligibility criteria included birth weight <1200 g 
and <48 hours of age. All infants had subcutaneous 
continuous glucose monitoring for the first week of life, 
with those in the intervention group receiving closed- 
loop insulin delivery in a prespecified window, between 
48 and 72 hours of age during which time the primary 
outcome was percentage of time in target (sensor 
glucose 4–8 mmol/L).
results The mean (SD) gestational age and birth 
weight of intervention and control study arms were 27.0 
(2.4) weeks, 962 (164) g and 27.5 (2.8) weeks, 823 
(282) g, respectively, and were not significantly different. 
The time in target was dramatically increased from 
median (IQR) 26% (6-64) with paper guidance to 91% 
(78-99) during closed loop (p<0.001). There were no 
serious adverse events and no difference in total insulin 
infused.
Conclusions Closed- loop glucose control based on 
subcutaneous glucose measurements appears feasible 
as a potential method of optimising glucose control in 
extremely preterm infants.
InTrODuCTIOn
Preterm infants are at high risk of both hypergly-
caemia and hypoglycaemia, related to deficits of 
insulin production and glycogen stores, with addi-
tive effects of parenteral nutrition, inotropic infu-
sions and sepsis- related insulin resistance, resulting 
in extremely variable insulin sensitivity.1 2 Hyper-
glycaemia is observed in 80% of extremely preterm 
infants, and glucose variability is associated with 
increased mortality and morbidity.2–6 Moreover, 
at a practical level glucose control is difficult to 
achieve in an extremely preterm infant; often 
requiring multiple changes of intravenous infusions, 
insulin dosing, requiring extra attention of staff and 
therefore increased cost. The use of sliding scale 
insulin therapy is widespread but considered subop-
timal as the desire to minimise blood sampling,7 
combined with the extremely variable response to 
insulin,1 puts these babies at risk from hypogly-
caemia.8 Babies are therefore often managed with 
a reduction in parenteral nutrition, and potentially 
inadequate nutritional support, when parenteral 
nutrition does not contribute as we might want to 
believe to hyperglycaemia and at a critical time of 
growth and development.9 10 
Continuous glucose monitoring (CGM) has been 
used in neonatal care to identify hypoglycaemia and 
is increasingly being considered as a potential adjunct 
to support clinical management.8 11–15 However, 
the wide variation in individual insulin sensitivity 
and limited staff resources within intensive care 
make it challenging for the full potential of CGM 
to be realised.14 Adaptive computerised algorithms 
using blood glucose (BG) measurements have been 
evaluated in adults16–18 and neonates undergoing 
intensive care.12 19 The addition of frequent glucose 
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closed- loop systems as recently investigated in adult intensive 
care patients.20 21 The present study hypothesised that closed- 
loop insulin delivery, based on subcutaneous CGM could be 
more effective in targeting glucose control in extremely preterm 




Babies were recruited from the neonatal intensive care unit at 
University of Cambridge Addenbrooke’s Hospital NHS Trust. 
All parents of eligible babies admitted to the unit within 48 hours 
of birth were approached (if a member of the research team was 
available to do so). The study applied a randomised, open- label, 
parallel design, with babies randomised to CGM alone supported 
by a paper algorithm or to CGM with an additional intervention 
period of closed- loop CGM. Ethics Committee approval, and 
informed written parental consent were obtained prior to study 
procedures. Eligibility criteria included birth weight <1200 g 
and age <48 hours. Babies were excluded if they had a major 
congenital malformation, an underlying metabolic disorder 
or the mother’s pregnancy had been complicated by diabetes. 
Criteria were chosen based on previous data that identified 
these infants as at most risk from glucose dysregulation, while 
avoiding potential bias.22
All babies had real- time (CGM) inserted which remained in 
situ for up to 7 days. The paper guideline advised on the use of 
insulin or additional dextrose support. For a prespecified period 
of 24 hours, between 48 and 72 hours postbirth, a closed- loop 
system controlled glucose in babies during the closed- loop inter-
vention, whereas babies in the control group continued to use 
CGM alongside the paper guideline. This window for closed- 
loop intervention was preselected as to be a standard time from 
birth in all babies, to allow time for informed parental consent 
to be obtained and as previous data (from masked CGM) had 
shown this to be the time when hyperglycaemia was most 
prevalent.22 Randomisation applied the minimisation methods 
using the Minim randomisation software,23 with stratification 
according to gestational age and birth weight.
Common study procedures
Apart from glucose control over the prespecified period, all 
other aspects of care were identical between treatment groups. 
BG monitoring was undertaken on the point- of- care BG metre 
StatStrip  metre (Nova Biomedical, Waltham, Massachusetts, 
USA). Actrapid insulin (Novo Nordisk, Bagsværd, Denmark) in 
concentration of 25 U/kg in 50 mL of 0.9% saline was used in 
both treatment groups. For CGM, an Enlite sensor (Medtronic, 
Watford, UK) was inserted by hand into the lateral thigh of each 
baby, and linked to the Paradigm Veo (Medtronic) for display 
of the sensor glucose (SG) concentration. Outside the interven-
tion period (48–72 hours), CGM data were used in combination 
with the paper algorithm, by the clinical team to guide glucose 
control in all babies. Nurses calibrated the CGM at least once 
every 12 hours with a BG measurement taken on the point- of- 
care BG metre.
Paper algorithm
The paper algorithm for insulin delivery has previously been 
described (see online supplementary appendix 1).14 It provided 
guidance based on the absolute SG value as well as glucose 
trends. If SG levels were outside of the target range it advised to 
review the clinical care, dextrose infusion rate and to consider 
modifying insulin delivery, which could be instigated by the 
nurse at the cot side. The insulin and dextrose were delivered by 
Alaris pumps (CareFusion, San Diego, California, USA).
Closed-loop glucose control between 48 and 72 hours
The closed- loop system comprised (i) Enlite sensor, (ii) a laptop 
computer running a model predictive control algorithm and (iii) 
two Alaris syringe pumps. We used a control algorithm based on 
the model predictive control approach,20 optimised and tuned 
in silico using a computer simulation environment validated 
for glucose control in the critically ill,24 and aiming to keep SG 
between 4.0 and 8.0 mmol/L. The algorithm calculated insulin 
requirements or, at low glucose values, 20% dextrose infusion 
rates based on real- time SG values. A study nurse entered SG 
values into the laptop and modified insulin and dextrose pumps 
as directed by the control algorithm every 15 min. During the 
closed- loop intervention, actrapid insulin in concentration of 
5 U/kg in 50 mL of 0.9% saline was used to allow for finer dose 
titration in accordance with the algorithm. The algorithm calcula-
tions used a compartment model of glucose kinetics25 describing 
the effect of insulin on SG excursions. The algorithm was 
initialised using a baby’s weight and adapted itself to a particular 
baby by updating two model parameters—a rapidly changing 
glucose flux correcting for errors in model- based predictions and 
a slowly changing estimate of an insulin rate to maintain normo-
glycaemia. The individualised model forecasted plasma glucose 
excursions over a 1.5 hour prediction horizon when calculating 
the insulin rate and a 30–40 min horizon when calculating the 
dextrose rate. Information about enteral or parenteral nutrition 
was not provided to the algorithm. A reference BG value was 
used every 6 hours for calibration of glucose sensor. If sensor 
readings were not available due to sensor failure or loss of data 
capture, then hourly BG levels were used to inform the algo-
rithm for up to 4 hours. At this time, the algorithm continued to 
provide advice every 15 min.
Assessments and data collection
Demographic and clinical characteristics were collected with 
antenatal variables defined as: antenatal steroids as having 
received at least one dose prior to delivery, prolonged rupture of 
membranes as rupture >24 hours prior to delivery, hypertension 
and chorioamnionitis were based on clinical diagnoses recorded 
in the maternal medical file. All BG measurements, insulin 
administration, type and volume of enteral and parenteral nutri-
tion and additional intravenous glucose administration were 
recorded from the time of randomisation to the end of CGM.
statistical analysis
The outcome measures and the statistical analysis plan were 
agreed in advance. Primary outcome being comparison of time 
SG in target glucose range 4.0–8.0 mmol/L between study arms. 
Secondary outcomes were time spent with SG levels between 
2.6 and 10.0 mmol/L, prevalence of hyperglycaemia (per cent 
time SG >10.0 mmol/L), mean and SD of SG. Safety end points 
included frequency of hypoglycaemia (any BG <2.6 mmol/L) 
and other adverse events. Sample size was selected to reflect this 
study as a pilot, to ensure we had comparable control data, while 
minimising patient exposure. Formal power calculations were 
not performed, and all analyses are based on intention to treat. 
Unpaired t- test was used to compare normally distributed vari-
ables. Non- normally distributed variables were compared using 
Mann- Whitney U test. Calculations were carried out using SPSS 
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Gestational age at birth (week) 27.0 (2.4) 27.5 (2.8)
Birth weight (g) 962 (164) 823 (282)
Sex (male:female) 5:5 5:5
Antenatal variables
  Antenatal steroids 10 (100%) 9 (90%)
  Maternal smoking 1 (10%) 2 (20%)
  Chorioamnionitis 2 (20%) 3 (30%)
  PROM 4 (40%) 4 (40%)
  Hypertension 1 (10%) 1 (10%)
Data are presented as mean (SD).
PROM, prolonged rupture of membranes (>24 hours).
Table 2 Comparison of glucose control, insulin delivery and 






Time spent with sensor glucose level 
(%)
4.0–8.0 mmol/L* 91 (78-99) 26 (6-64) <0.001
2.6–10 mmol/L 100 (94-100) 84 (46-98) 0.133
>10.0 mmol/L 0 (0-6) 16 (2-54) 0.113
<2.6 mmol/L 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.720
Baseline sensor glucose (mmol/L) 7.9 (6.9-11.5) 8.2 (7.0-12.4) 0.182
Mean sensor glucose (mmol/L) 6.2 (6.1-7.1) 8.6 (7.4-11.1) 0.002
SD of sensor glucose (mmol/L) 1.0 (0.8-1.9) 1.3 (0.9-2.5) 0.604
Episodes of blood glucose 
<2.6 mmol/L†
1 0 1.000
Insulin (U/kg/hour) 0.04 (0.03-0.07) 0.02 (0.00-0.11) 0.400
Nutritional intake
Dextrose (mg/kg/min) 8.4 (7.2-10.3) 8.5 (4.2-10.6) 0.604
Protein (g/kg/day) 3.2 (2.5-4.1) 3.5 (1.6-4.1) 1.000
Lipid (g/kg/day) 1.8 (1.0-1.8) 1.4 (0.9-2.2) 0.905
Trophic feeds 4 4 1.000
Data are presented as median (IQR).
*Primary end point.
†Present at start of closed- loop study period prior to computer algorithm advice being initiated.
SD or median (IQR). P value <0.05 was considered to be statis-
tically significant.
resulTs
Twenty- one babies were randomly assigned, between study arms, 
but one baby in the control group died within 48 hours of birth, 
so was excluded from the analyses. Baseline characteristics of 
the two groups (n=20) were similar (table 1). There were no 
significant problems with sensor insertion or removal, with only 
one baby (control group) having a sensor replaced as there was 
no connection to the monitor. All 20 babies remained in the 
study throughout the intervention period from 48 to 72 hours 
with comparable amount of SG data available for analyses 
in each group (median (IQR) for both study groups 24 hours 
(23.75, 24.00)). Control algorithm directed insulin therapy 
was followed, at all times, during the prespecified 48–72 hours 
period. The maximum period of sensor signal loss during the 
closed loop was 3.5 hours, during which hourly BG values were 
used by the control algorithm. For the remaining study, there 
was minimal loss of data: one baby in the ‘control’ group was 
transferred out of the unit on study day 5, and one baby in the 
closed- loop arm died on study day 6, so no further data could 
be collected. Therefore, the mean (SD) length of glucose data 
collected in each study arm were 137 (16.4) hours and 136 (8.7) 
hours for CGM and CGM plus closed loop, respectively.
Glucose control, insulin and dextrose administration between 
48 and 72 hours
There was no difference in the baseline mean SG at 48 hours 
between study groups (table 2). During the intervention 
period, the median (IQR) time spent in the target range (SG 
4.0–8.0 mmol/L) was significantly higher in babies in the closed- 
loop group 91% (78, 99) compared with controls 26% (6-64); 
p<0.001—equivalent to 22 (19-24) hours in the ‘closed loop’ 
versus 6 (1-15) hours in the control group. Similarly, the time 
spent in the wider target range 2.6–10.0 mmol/L was higher in the 
closed- loop group: median 100% compared with control group, 
median 84%. This was due to the smaller per cent of time with 
SG values >10 mmol/L with median 16% in the control group 
compared with median 0% in the closed- loop group. There was 
no difference in the time spent with SG levels <2.6 mmol/L. 
Lower SG was observed in the closed- loop group median (IQR) 
6.2 (6.1-7.1) mmol/L compared with the control group 8.6 (7.4-
11.1) mmol/L (p=0.002). Glucose variability as measured by the 
SD of SG was similar (p=0.604).
The summative glucose profiles and insulin infused 
are provided in figure 1. Nine out of the 10 babies in the 
closed- loop group had received insulin prior to the 24 hours 
intervention with the one remaining baby being started on 
insulin during the 24 hours closed loop. This compared with 
four babies in the control arm having received insulin prior 
to, and eight babies receiving insulin during the intervention 
period. Four babies in the closed- loop study arm received 
additional 20% dextrose for short periods during the inter-
vention period (up to 3.5 hours). The mean infusion rate 
in these babies ranged from 0.13 to 0.53 mL/kg/hour. The 
highest rate being infused in a baby who was hypoglycaemia 
prior to the start of the closed- loop intervention. There 
was no statistical difference in the total amount of insulin 
infused or nutritional intake between study groups during 
the 24 hours intervention period.
Glucose control, insulin and dextrose administration between 
72 and 160 hours
In the postintervention period, after 72 hours, there was a trend 
of increased time in both glucose target ranges (4.0–8.0 and 
2.6–10.0 mmol/L) in the closed- loop group compared with the 
control group (table 3), but these differences did not reach statis-
tical significance.
nutrition and clinical care
All babies received parenteral and enteral nutrition according 
to the standard local neonatal unit protocol. During the 
closed- loop intervention period between 48 and 72 hours, 
four babies in each study group were receiving minimal 
amounts of trophic feeds. In the postintervention period, 
after 72 hours, there was no difference in the volumes of 
milk received between the two study groups (table 3). None 
of the babies received hydrocortisone, but seven babies in 
the control arm and two in the intervention arm received 
inotropes during the first week. During the intervention 
period, the median (IQR) number of BG values taken per 
day was 5.50 (4.75-6.56) in the control group compared 
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Figure 1 Glucose control and insulin delivery median (IQR) of sensor glucose and insulin infused in babies randomised to closed- loop management 
or continuous glucose monitoring with paper algorithm (control). The closed- loop intervention period is denoted by the vertical lines, and the target 
glucose range 4.0–8.0 mmol/L is denoted by horizontal lines.
Table 3 Comparison of glucose control, insulin delivery and 






Time spent with sensor glucose 
level (%)
4.0–8.0 mmol/L 64 (39-90) 42 (30-55) 0.053
2.6–10 mmol/L 95 (79-97) 78 (61-97) 0.243
>10 mmol/L 3 (1-21) 22 (3-36) 0.156
<2.6 mmol/L 0.0 (0.0-0.8) 0.0 (0.0-0.2) 0.720
Mean sensor glucose (mmol/L) 7.0 (6.8-8.5) 8.3 (7.3-9.2) 0.182
SD of sensor glucose (mmol/L) 1.7 (1.5-2.1) 1.7 (1.3-2.8) 0.780
Episodes of blood glucose 
<2.6 mmol/L
1 0 1.000
Insulin (U/kg/hour) 0.02 (0.00-0.04) 0.03 (0.00-0.05) 0.356
Nutritional intake
  Dextrose (mg/kg/min) 9.4 (7.0-10.6) 8.7 (5.4-10.9) 0.549
  Protein (g/kg/day) 3.7 (2.7-4.3) 3.8 (2.9-4.4) 0.968
  Lipid (g/kg/day) 2.0 (1.5-2.9) 1.8 (1.2-2.8) 0.611
  Oral milk intake (mL/kg/day) 4.4 (3.5-11.5) 5.0 (0.5-13.0) 0.720
Data are presented as median (IQR).
whole study period 5.14 (4.29-5.43) in the control compared 
with 5.29 (4.64-5.80) in the intervention group.
safety
There were no reported concerns about the sensor site in 
terms of inflammation or infection either during the study or 
after removal. In the closed- loop study group, there were two 
babies who had documented episodes of hypoglycaemia with 
BG <2.6 mmol/L. One episode occurred when checking the 
baseline BG prior to the onset of closed loop, at this time main-
tenance fluids were being changed, but no insulin was being 
infused. The second episode was on day 6, again associated with 
a change of maintenance fluids. There were a further two babies 
who had periods (after the 72 hours closed loop) when SG fell to 
below 2.6 mmol/L but the BG at this time was documented above 
2.6 mmol/L. In the control study group, no babies had a docu-
mented BG value <2.6 mmol/L. One baby in the control group 
had an episode lasting 205 min when the SG fell to <2.6 mmol/L 
(BG was not checked at this time). None of the babies were on 
insulin, and there was no clinical evidence of hypoglycaemia in 
these babies during any of these episodes.
DIsCussIOn
This study is the first to show that a closed- loop system using 
subcutaneous glucose measurements to guide insulin delivery 
may improve glucose control in extremely preterm infants. This 
new approach could represent a step- change in care, providing 
greater safety and tighter control while minimising staff time at 
bedside and changes in fluid/insulin treatment. Compared with 
CGM alone, closed- loop intervention increased the time  when 
SG was in the target range of 4 to 8 mmol/L threefold. In the 
high- intensity and high- cost setting of neonatal intensive care, 
this preliminary data support further development of closed- 
loop systems, with real- time glucose- responsive insulin and 
dextrose delivery to support the care of these babies.
Reflecting the current controversy regarding optimal targets 
for glucose control in neonatal intensive care, we adopted a 
moderate glucose target range between 4.0 and 8.0 mmol/L 
rather than the tight glycaemic regimen of Leuven and NICE- 
SUGAR (Normoglycaemia in Intensive Care Evaluation and 
Survival Using Glucose Algorithm Regulation) studies.26 27 These 
moderate target ranges represent physiological in utero levels,28 
and the upper threshold reflects a postnatal glucose level which 
has been associated with increased mortality and morbidity in 
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in these babies remains to be determined and this study does not 
resolve this long- standing debate in the field. It rather shows 
how an automated system can be used to achieve control to a 
given target range.
Different strategies are currently used to target glucose control 
in the preterm infant, each with different risks and benefits. A 
reduction in dextrose load risks compromised nutritional intake, 
while insulin therapy can lead to hypoglycaemia. The level of 
insulin use within this study is likely to reflect both the extreme 
prematurity of the babies recruited and the current practice on 
our unit, which aims to ‘optimise’ nutritional delivery. In this 
study, there were no episodes of hypoglycaemia related to advice 
from the closed- loop algorithm, but the use of the CGM high-
lighted clinically silent episodes of hypoglycaemia in both study 
arms, independent of insulin use. The prevalence of hypogly-
caemia was comparable to that reported by others in this popu-
lation (27%),30 and to that reported using masked CGM which 
highlights prolonged periods of clinically silent hypoglycaemia.22
The CGM were calibrated using the StatStrip metre that is 
validated for use in neonates and has the Food and Drug Admin-
istration approval for use in intensive care.31 These metres were 
used, as they were the standard of care for clinical management 
within the neonatal unit. Although there remains controversy 
regarding the clinical significance of clinically silent episodes of 
hypoglycaemia detected on CGM, there is recent evidence of an 
association between these episodes with substantially increased 
risk of impaired executive function and visual motor difficulty 
at 4.5 years.32
The frequency of BG sampling in preterm infants is typically 
much lower than in adults and children in intensive care and 
therefore the use of CGM has the potential to have an even 
greater impact. Differences in frequency of BG monitoring may 
have had an impact on level of glucose control. However, within 
the control arm babies had >4 BG values taken every 24 hours 
in the first 3 days of life. Of note, the strength of insulin in 
the intervention period was more dilute than in the compara-
tive control group to allow for more frequent changes in dose 
titration. Despite randomisation, there were a larger number 
of babies in the control arm who received inotropes during the 
first week, and inotropic drugs will reduce insulin secretion 
and insulin sensitivity. However, given the pattern of improved 
glucose control during the intervention we do not think these 
differences could account for the differences in glucose control 
that were observed.
Previous studies have explored the potential for the use of 
CGM to guide changes in dextrose delivery,12 these studies 
though remained dependent on staff responding to trends or 
alarms in SG before intervening.12 This contrasts with the present 
study in which the targeting of glucose control is proactively 
driven by the closed- loop algorithm, which was responding to 
frequently sampled SG data. This study is unique in exploring 
a control approach belonging to the family of model predictive 
control algorithms and optimised on a validated computer simu-
lation environment24 prior to study commencement to ensure a 
favourable outcome.
The strengths of our study are the randomised controlled 
study design and comparability of the study groups and nutri-
tional intakes. The study limitations include a small sample size, 
where despite randomisation there can remain base line differ-
ences between study groups. Although the study groups appear 
comparable, more babies in the control group compared with the 
intervention group were on inotropes, and more babies in the 
intervention arm were on insulin at the start of study interven-
tion. In such a design, it was not possible to blind the clinicians 
to the intervention. The study duration was short, and as it is 
known that insulin sensitivity varies over time from birth, how 
the algorithm works over longer periods would be important 
to explore. As a single- centre study design, where nutritional 
policies and practices will vary in comparison to other units 
it would be important to test the algorithm in different units 
with different nutritional strategies to test generalisability. The 
algorithm was not designed to alter nutritional delivery, as this 
was predetermined by the clinical team; with the interven-
tion designed as a simple adjunct to support targeting glucose 
control, alongside the clinical plan for nutritional support. Alter-
native designs might consider a combined approach to guide 
nutritional intake alongside insulin treatment. Further studies 
are required to explore the impact of a fully automated system 
with infusion pumps providing insulin and 20% dextrose under 
fully automated computer control.
This is the first randomised study to evaluate the feasibility 
of a closed- loop control, based on CGM in preterm infants to 
guide insulin delivery to support glucose control. This closed- 
loop system appears a potential adjunct for targeting glucose 
control in preterm infants requiring intensive care and warrants 
further study.
Acknowledgements The authors would like to thank all the families that took 
part in the study and the hard work of all the clinical team in the Neonatal Unit in 
supporting this study. We would also like to thank the Evelyn Trust, the National 
Institute of Health Research EME Programme and Medtronic for without whom 
the study would not have been possible and our joint Sponsors the University of 
Cambridge and Cambridge University Hospitals NHS Trust.
Contributors KB was the principal investigator who had the original idea for the 
study and contributed to the study design, to the acquisition and analysis of the 
data prior to drafting the initial manuscript and subsequent critical revisions. LT 
contributed to the design of the study, to the acquisition of the data and drafting of 
the manuscript. DE contributed to the analysis of the data collected during the study, 
and critically reviewed the manuscript. RH contributed to the design of the study 
and in particular the model predictive computer algorithm, to the interpretation of 
the data, critical revision of the initial drafts of the manuscript. DBD contributed to 
the design of the study, evaluation of the data, critical review and revision of the 
manuscript. All authors have approved the final manuscript prior to submission and 
are accountable for the integrity of the study. 
Funding Funding was provided by the Evelyn Trust, the National Institute of Health 
Research EME Programme and the National Institute of Health Research Cambridge 
Biomedical Research Centre. Medtronic provided the continuous glucose monitoring 
systems and sensors. 
Disclaimer Medtronic had no role in design of the study, the gathering of data, 
access to data, preparation of the manuscript or decision to publish the results.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Requests for anonymised data should be made to the 
corresponding author.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
OrCID iD
Kathryn Beardsall http:// orcid. org/ 0000- 0003- 3582- 183X
RefeRences
 1 Mitanchez D. Glucose regulation in preterm newborn infants. Horm Res 
2007;68:265–71.
 2 Beardsall K, Vanhaesebrouck S, Ogilvy- Stuart AL, et al. Prevalence and determinants of 





















F284 Beardsall K, et al. Arch Dis Child Fetal Neonatal Ed 2020;105:F279–F284. doi:10.1136/archdischild-2019-316871
Original research
 3 Blanco CL, McGill- Vargas LL, McCurnin D, et al. Hyperglycemia increases the risk of 
death in extremely preterm baboons. Pediatr Res 2013;73:337–43.
 4 Alsweiler JM, Harding JE, Bloomfield FH. Neonatal hyperglycaemia increases mortality 
and morbidity in preterm lambs. Neonatology 2013;103:83–90.
 5 Alexandrou G, Skiöld B, Karlén J, et al. Early hyperglycemia is a risk 
factor for death and white matter reduction in preterm infants. Pediatrics 
2010;125:e584–91.
 6 Ogilvy- Stuart AL, Beardsall K. Management of hyperglycaemia in the preterm infant. 
Arch Dis Child Fetal Neonatal Ed 2010;95:F126–31.
 7 Jacobsen T, Grønvall J, Petersen S, et al. "Minitouch" treatment of very low- birth- 
weight infants. Acta Paediatr 1993;82:934–8.
 8 Uettwiller F, Chemin A, Bonnemaison E, et al. Real- time continuous glucose 
monitoring reduces the duration of hypoglycemia episodes: a randomized trial in very 
low birth weight neonates. PLoS One 2015;10:e0116255.
 9 Morgan C. The potential risks and benefits of insulin treatment in hyperglycaemic 
preterm neonates. Early Hum Dev 2015;91:655–9.
 10 Zamir I, Tornevi A, Abrahamsson T, et al. Hyperglycemia in Extremely 
Preterm Infants- Insulin Treatment, Mortality and Nutrient Intakes. J Pediatr 
2018;200:104–10.
 11 Beardsall K, Ogilvy- Stuart AL, Ahluwalia J, et al. The continuous glucose monitoring 
sensor in neonatal intensive care. Arch Dis Child Fetal Neonatal Ed 2005;90:F307–10.
 12 Galderisi A, Facchinetti A, Steil GM, et al. Continuous Glucose Monitoring in Very 
Preterm Infants: A Randomized Controlled Trial. Pediatrics 2017;140:e20171162.
 13 Stewart ZA, Thomson L, Murphy HR, et al. A Feasibility Study of Paired Continuous 
Glucose Monitoring Intrapartum and in the Newborn in Pregnancies Complicated by 
Type 1 Diabetes. Diabetes Technol Ther 2019;21:20–7.
 14 Thomson L, Elleri D, Bond S, et al. Targeting glucose control in preterm infants: 
pilot studies of continuous glucose monitoring. Arch Dis Child Fetal Neonatal Ed 
2019;104:F353–9.
 15 McKinlay CJD, Chase JG, Dickson J, et al. Continuous glucose monitoring in neonates: 
a review. Matern Health Neonatol Perinatol 2017;3:18.
 16 Cordingley JJ, Vlasselaers D, Dormand NC, et al. Intensive insulin therapy: enhanced 
Model Predictive Control algorithm versus standard care. Intensive Care Med 
2009;35.
 17 Preiser JC, Devos P, Ruiz- Santana S, et al. A prospective randomised multi- centre 
controlled trial on tight glucose control by intensive insulin therapy in adult intensive 
care units: the Glucontrol study. Intensive Care Med 2009;35:1738–48.
 18 Pachler C, Plank J, Weinhandl H, et al. Tight glycaemic control by an automated 
algorithm with time- variant sampling in medical ICU patients. Intensive Care Med 
2008;34:1224–30.
 19 Le Compte A, Chase JG, Lynn A, et al. Blood glucose controller for neonatal intensive 
care: virtual trials development and first clinical trials. J Diabetes Sci Technol 
2009;3:1066–81.
 20 Leelarathna L, English SW, Thabit H, et al. Feasibility of fully automated closed- loop 
glucose control using continuous subcutaneous glucose measurements in critical 
illness: a randomized controlled trial. Crit Care 2013;17:R159.
 21 Leelarathna L, English SW, Thabit H, et al. Accuracy of subcutaneous continuous 
glucose monitoring in critically ill adults: improved sensor performance with enhanced 
calibrations. Diabetes Technol Ther 2014;16:97–101.
 22 Beardsall K, Vanhaesebrouck S, Ogilvy- Stuart AL, et al. Early insulin therapy in very- 
low- birth- weight infants. N Engl J Med 2008;359:1873–84.
 23 Evans S, Day S, Royston P. Minim: minimisation program for allocating patients to 
treatments in clinical trials. http:// www- users. york. ac. uk/~ mb55/ guide/ minimins. doc
 24 Wilinska ME, Blaha J, Chassin LJ, et al. Evaluating glycemic control algorithms by 
computer simulations. Diabetes Technol Ther 2011;13:713–22.
 25 Hovorka R, Shojaee- Moradie F, Carroll PV, et al. Partitioning glucose distribution/
transport, disposal, and endogenous production during IVGTT. Am J Physiol Endocrinol 
Metab 2002;282:E992–1007.
 26 Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients 
in paediatric intensive care: a prospective, randomised controlled study. Lancet 
2009;373:547–56.
 27 Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in 
critically ill patients. N Engl J Med 2009;360:1283–97.
 28 Economides DL, Nicolaides KH, Campbell S. Metabolic and endocrine findings 
in appropriate and small for gestational age fetuses. J Perinat Med 1991;19(1-
2):97–105.
 29 Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and 
morbidity in extremely low birth- weight infants. Pediatrics 2006;118:1811–8.
 30 Alsweiler JM, Harding JE, Bloomfield FH. Tight glycemic control with insulin 
in hyperglycemic preterm babies: a randomized controlled trial. Pediatrics 
2012;129:639–47.
 31 FDA rcommendations for all Hosptial patients including ITU.
 32 McKinlay CJD, Alsweiler JM, Anstice NS, et al. Association of Neonatal Glycemia With 
Neurodevelopmental Outcomes at 4.5 Years. JAMA Pediatr 2017;171:972–83. copyright.
 on N
ovem











d: first published as 10.1136/archdischild-2019-316871 on 9 A
ugust 2019. D
ow
nloaded from
 
